Show simple item record

dc.contributor.authorCaimari, Fen_US
dc.contributor.authorKorbonits, Men_US
dc.date.accessioned2016-11-25T17:18:31Z
dc.date.available2016-08-24en_US
dc.date.issued2016-10-15en_US
dc.date.submitted2016-11-08T00:44:23.893Z
dc.identifier.issn1078-0432en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/17893
dc.descriptionF. Caimari was supported by the Fundación Alfonso Martin Escudero fellowship.
dc.description.abstractRecently, a number of novel genetic alterations have been identified that predispose individuals to pituitary adenomas. Clinically relevant pituitary adenomas are relatively common, present in 0.1% of the general population. They are mostly benign monoclonal neoplasms that arise from any of the five hormone-secreting cell types of the anterior lobe of the pituitary gland, and cause disease due to hormonal alterations and local space-occupying effects. The pathomechanism of pituitary adenomas includes alterations in cell-cycle regulation and growth factor signaling, which are mostly due to epigenetic changes; somatic and especially germline mutations occur more rarely. A significant proportion of growth hormone- and adrenocorticotrophin-secreting adenomas have activating somatic mutations in the GNAS and USP8 genes, respectively. Rarely, germline mutations predispose to pituitary tumorigenesis, often in a familial setting. Classical tumor predisposition syndromes include multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) syndromes, Carney complex, and McCune-Albright syndrome. Pituitary tumors have also been described in association with neurofibromatosis type 1, DICER1 syndrome, and SDHx mutations. Pituitary adenomas with no other associated tumors have been described as familial isolated pituitary adenomas. Patients with AIP or GPR101 mutations often present with pituitary gigantism either in a familial or simplex setting. GNAS and GPR101 mutations that arise in early embryonic age can lead to somatic mosaicism involving the pituitary gland and resulting in growth hormone excess. Senescence has been suggested as the key mechanism protecting pituitary adenomas turning malignant in the overwhelming majority of cases. Here we briefly summarize the genetic background of pituitary adenomas, with an emphasis on the recent developments in this field. Clin Cancer Res; 22(20); 5030-42. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "ENDOCRINE CANCERS REVISING PARADIGMS".en_US
dc.description.sponsorshipF. Caimari was supported by the Fundación Alfonso Martin Escudero fellowshipen_US
dc.format.extent5030 - 5042en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofClin Cancer Resen_US
dc.subjectAdenomaen_US
dc.subjectChromograninsen_US
dc.subjectEndopeptidasesen_US
dc.subjectEndosomal Sorting Complexes Required for Transporten_US
dc.subjectGTP-Binding Protein alpha Subunits, Gsen_US
dc.subjectGerm-Line Mutationen_US
dc.subjectHumansen_US
dc.subjectPituitary Gland, Anterioren_US
dc.subjectPituitary Neoplasmsen_US
dc.subjectProto-Oncogene Proteinsen_US
dc.subjectUbiquitin Thiolesteraseen_US
dc.titleNovel Genetic Causes of Pituitary Adenomas.en_US
dc.typeArticle
dc.identifier.doi10.1158/1078-0432.CCR-16-0452en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/27742789en_US
pubs.issue20en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume22en_US
dcterms.dateAccepted2016-08-24en_US
qmul.funderUnderstanding the pathogenic role of AIP in pituitary adenoma tumour formation::Rosetrees Trusten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record